Diagnosing Chronic Arsenic Exposure

Laboratory Testing Approach

The American College of Occupational and Environmental Medicine recommends 24-hour urine collection as the gold standard for diagnosing chronic arsenic exposure, as it reflects ongoing exposure better than blood levels, which are transitory 3
Spot urine samples are acceptable alternatives when 24-hour collection is impractical, according to the National Institute for Occupational Safety and Health 3
Testing must be performed by OSHA-designated laboratories using inductively coupled plasma-mass spectrometry (ICP-MS), as stated by the Occupational Safety and Health Administration 3

Seafood consumption can dramatically elevate urinary arsenic levels without any clinical toxicity, creating a major diagnostic pitfall, as noted by the Environmental Protection Agency 1, 2
Organic arsenic compounds from seafood are relatively non-toxic and rapidly excreted unchanged in urine within 24-48 hours, according to the World Health Organization 4, 5
The Centers for Disease Control and Prevention advises against dismissing elevated urinary arsenic in patients reporting high seafood consumption, as organic arsenic can mask concurrent toxic inorganic arsenic exposure 2

The National Institute of Environmental Health Sciences recommends testing drinking water sources in high-risk geographic areas, including Southwest, New England, upper Midwest, and Western United States, where groundwater naturally contains elevated arsenic 2

The Agency for Toxic Substances and Disease Registry suggests obtaining detailed exposure history focusing on water sources, occupation, and seafood consumption, and performing thorough skin examination for melanosis and hyperkeratosis patterns 1, 2
The American College of Preventive Medicine recommends ordering 24-hour urine arsenic after 3-5 days of seafood avoidance, and testing drinking water source for arsenic concentration 4, 5, 3

The International Agency for Research on Cancer advises that patients with confirmed chronic arsenic exposure require lifelong surveillance for malignancies, particularly skin, lung, and bladder cancers 2